Community-based Malaria Screening and Treatment for Pregnant Women Receiving Standard Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: A Multicenter (The Gambia, Burkina Faso, and Benin) Cluster-randomized Controlled Trial

Scott, Susana; D’Alessandro, Umberto; Kendall, Lindsay; Bradley, John; Bojang, Kalifa; Correa, Simon; Njie, Fanta; Tinto, Halidou; Traoré-Coulibaly, Maminata; Natama, Hamtandi Magloire; Ousmane, Traore; Valéa, Innocent; Nahum, Alain; Ahounou, Daniel; Bohissou, Francis; Sondjo, Gethaime; Agbowaï, Carine; Mens, Pètra F.; Ruizendaal, Esmée; Schallig, Henk D. F. H.; Dierickx, Susan; Grietens, Koen Peeters; Duval, Laetitia; Conteh, Lesong; Drabo, Maxime; Guth, Jamie; Pagnoni, Franco

doi:10.1093/cid/ciy522

Cited by 31 publications

(35 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings of this study showed that 42.4% of the pregnant women adhered to the WHO-recommended ≥3 IPTp-SP doses. This finding was consistent with similar reports in the Western region of Ghana (47.7%) [ 30 ], Burkina Faso (49.2%) [ 33 ], and Tanzania (40.6–52.6) [ 34 ]. However, our measured percentage of reproted IPTp-SP uptake (42.4%) was higher than published ranges in Uganda (7.0-8.0%) [ 35 ], north-western Tanzania (6.0%) [ 28 ], and Gambia (3.8%) [ 33 ].…”

Section: Discussionsupporting

confidence: 93%

“…This finding was consistent with similar reports in the Western region of Ghana (47.7%) [ 30 ], Burkina Faso (49.2%) [ 33 ], and Tanzania (40.6–52.6) [ 34 ]. However, our measured percentage of reproted IPTp-SP uptake (42.4%) was higher than published ranges in Uganda (7.0-8.0%) [ 35 ], north-western Tanzania (6.0%) [ 28 ], and Gambia (3.8%) [ 33 ]. This might be due to differences in implementation challenges, procurement bottlenecks, variations in the intensity of malaria transmission geographically, health worker delays, and irregular subscription of the IPTp-SP services by pregnant women [ 16 , 29 , 30 , 36 , 37 ].…”

Section: Discussionsupporting

confidence: 93%

“…Again, the prevalence of malaria at 36 weeks of gestation was significantly decreased from 35.8% in non-SP dose users, compared to 16.9% in ≥3 SP dose users. The post IPTp-SP malaria prevalence was inconsistent with published percentages in Benin (4–16%) [ 37 ], Nigeria (7.7%) [ 33 ], and Ghana (7.9–11.2%) [ 25 , 38 ]. Antenatal clinics play a significant role in combating maternal and infant mortality.…”

Section: Discussionmentioning

confidence: 67%

See 2 more Smart Citations

The Effectiveness of the Revised Intermittent Preventive Treatment with Sulphadoxine Pyrimethamine (IPTp-SP) in the Prevention of Malaria among Pregnant Women in Northern Ghana

Agyeman

Newton

Annor³

et al. 2020

Journal of Tropical Medicine

View full text Add to dashboard Cite

This study investigated the effectiveness of the World Health Organization (WHO)-revised Intermittent Preventive Treatment using Sulphadoxine Pyrimethamine (IPTp-SP) dosage regimen in the prevention of malaria infections in pregnancy. The study involved a prospective cohort of pregnant women who attended the antenatal clinic in four health facilities (Tamale Teaching Hospital, Tamale West Hospital, Tamale Central Hospital, and Tamale SDA Hospital) within the Tamale metropolis. Data collection spanned a period of 12 months, from September 2016 to August 2017, to help account for seasonality in malaria. The study included 1181 pregnant women who attended antenatal clinics in four hospitals within the metropolis. The registers at the facilities served as a sampling frame, and the respondents were randomly sampled out from the number of pregnant women available during each visit. They were enrolled consecutively as they kept reporting to the facility to receive antenatal care. The participants were stratified into three groups; the no IPTp-SP, <3 doses of IPTp-SP, and ≥3 doses of IPTp-SP. The participants were followed up until 36 weeks of gestation, and blood samples were analyzed to detect the presence of peripheral malaria parasites. At the end of the study, 42.4% of the women had taken at least 3 doses of SP based on the revised WHO IPTp-SP policy. Pregnant women who had taken at least 3 doses of IPTp-SP had a malaria prevalence of 16.9% at 36 weeks of gestation, compared to 35.8% of those who had not taken IPTp-SP. In the multivariable logistic regression, those who had taken ≥3 doses of SP were associated with 56% reduced odds (aOR 0.44, CI 0.27–0.70, P = 0.001 ) of late gestational peripheral malaria, compared with those who did not take SP. IPTp-SP served under three or more doses provided a dose-dependent protection of 56% against maternal peripheral malaria parasitaemia detectable at the later stages of gestation (36 weeks). Since the dose-dependent potency of IPTp-SP depletes with time, there is the need for research into more sustainable approaches that offer longer protection.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 67%

See 1 more Smart Citation

The Effectiveness of the Revised Intermittent Preventive Treatment with Sulphadoxine Pyrimethamine (IPTp-SP) in the Prevention of Malaria among Pregnant Women in Northern Ghana

Agyeman

Newton

Annor³

et al. 2020

Journal of Tropical Medicine

View full text Add to dashboard Cite

show abstract

“…Only two women were found to carry a double dhps 437/540 mutant allele at delivery. Of note, data on dhfr - dhps mutations among the study popualtion were obtained from the main COSMIC trial [ 36 , 37 ] and re-analysed in this manuscript.…”

Section: Resultsmentioning

confidence: 99%

“…Between 2013 and 2016, a multi-centre, cluster-randomized, controlled trial (COSMIC) was conducted in three West African countries with high (Burkina Faso, Benin) and low (The Gambia) malaria transmission, to assess the protective efficacy of adding community-scheduled screening and treatment of malaria during pregnancy (CSST) to standard IPTp-SP (CSST/IPTp-SP) [ 35 , 36 ]. The CSST/IPTp-SP strategy was based on monthly active follow-up by community health workers using rapid diagnostic tests (RDTs).…”

Section: Introductionmentioning

confidence: 99%

Prevalence and factors associated with carriage of Pfmdr1 polymorphisms among pregnant women receiving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) and artemether-lumefantrine for malaria treatment in Burkina Faso

Natama

Rouamba

Bazié

et al. 2020

Malar J

Self Cite

View full text Add to dashboard Cite

Background Single nucleotide polymorphisms occurring in the Plasmodium falciparum multidrug resistant gene 1 (pfmdr1) are known to be associated with aminoquinoline resistance and, therefore, represent key P. falciparum markers for monitoring resistance both in susceptible groups (children under 5 years old and pregnant women) and in the general population. This study aimed to determine prevalence and factors associated with the carriage of pfmdr1 N86Y, Y184F and D1246Y polymorphisms among pregnant women in a setting of high malaria transmission in Burkina Faso. Methods Plasmodium falciparum isolates were collected at the first antenatal care visit (ANC-1) as well as at delivery from pregnant women participating in the COSMIC trial (NTC01941264), which assessed malaria preventive interventions during pregnancy in the Nanoro Health District. Here, pregnant women received intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) and malaria infections and/or diseases were treated using artemether-lumefantrine (AL) during the trial. Parasite DNA was extracted from dried blood spots and the presence of pfmdr1 mutations at positions 86, 184 and 1246 was determined using nested PCR, followed by restriction fragment length polymorphism (RFLP) analysis. Results A prevalence of 13.2% (20/151) and 12.1% (14/116) of the pfmdr1 86Y mutant allele was found at ANC-1 and at delivery, respectively, while no mutant allele was observed for Y184F and D1246Y codons at both ANC-1 and at delivery. There were no significant factors associated with pfmdr1 86Y mutant allele carriage at ANC-1. However, malaria infections at delivery with a parasite density above the median (2237.2 (IQR: 613.5–11,425.7) parasites/µl) was associated with an increase risk of pfmdr1 86Y mutant allele carriage (AOR = 5.5 (95% CI 1.07–28.0); P = 0.04). In contrast, both three or more IPTp-SP doses (AOR = 0.25 (95% CI 0.07–0.92); P = 0.04) and one or more AL treatment (AOR = 0.25 (95% CI 0.07–0.89); P = 0.03) during pregnancy were associated with a significant reduce risk of pfmdr1 86Y mutant allele carriage at delivery. Conclusion These findings suggest that both high coverage of IPTp-SP and the use of AL for the treatment of malaria infection/disease during pregnancy select for pfmdr1 N86 wild-type allele at delivery.

show abstract

Antenatal care positive responses to pregnant women in preventing and controlling malaria in pregnancy: the sub-Saharan African perspective

2022

View full text Add to dashboard Cite

Community-based Malaria Screening and Treatment for Pregnant Women Receiving Standard Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: A Multicenter (The Gambia, Burkina Faso, and Benin) Cluster-randomized Controlled Trial

Abstract: NCT01941264; ISRCTN37259296.

Cited by 31 publications

References 26 publications

The Effectiveness of the Revised Intermittent Preventive Treatment with Sulphadoxine Pyrimethamine (IPTp-SP) in the Prevention of Malaria among Pregnant Women in Northern Ghana

The Effectiveness of the Revised Intermittent Preventive Treatment with Sulphadoxine Pyrimethamine (IPTp-SP) in the Prevention of Malaria among Pregnant Women in Northern Ghana

Prevalence and factors associated with carriage of Pfmdr1 polymorphisms among pregnant women receiving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) and artemether-lumefantrine for malaria treatment in Burkina Faso

Antenatal care positive responses to pregnant women in preventing and controlling malaria in pregnancy: the sub-Saharan African perspective

Contact Info

Product

Resources

About